Collagen peptides is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of collagen peptides varies by country and intended use. In the United States, they are typically marketed as dietary supplements or food ingredients, and certain uses may be generally recognized as safe (GRAS) through self-affirmation or notification. In the European Union, collagen peptides from approved animal sources are considered food, not novel foods, if they have a history of consumption. Health claims linking collagen peptides to joint or skin benefits are not approved in the US or EU. Labeling must list the animal source and may state the protein content.
Manufacturing collagen peptides begins with collagen-rich raw materials such as bovine hide, porcine skin, fish scales, or poultry cartilage, which undergo washing, size reduction, and pretreatment to remove non-collagen proteins and fats. Extraction may use acid, alkali, or heat. Hydrolysis then breaks the collagen into smaller peptides, often with enzymes such as pepsin, papain, or alcalase. Process conditions of time, temperature, pH, and enzyme dose determine the final molecular weight distribution. After hydrolysis, the solution is filtered, concentrated, and dried into powder.
Quality testing of collagen peptides relies on several analytical methods. Molecular weight distribution is commonly measured by size-exclusion chromatography, sometimes paired with multi-angle light scattering. Amino acid composition is determined by ion-exchange chromatography or reversed-phase high-performance liquid chromatography after acid hydrolysis, while protein content is estimated by Kjeldahl or Dumas nitrogen analysis. Moisture, ash, and heavy metals are checked against specification limits. These tests help ensure consistency and detect adulteration with other proteins.
Collagen peptides differ from gelatin in degree of hydrolysis and chain length. Gelatin forms gels when cooled, whereas extensively hydrolyzed collagen peptides generally remain soluble over a wider temperature range; this difference arises because shorter peptides lose the ordered structure needed for gel network formation. Products may be standardized by molecular weight, amino acid content, or solubility, but no single specification applies to all collagen peptides. Source material, hydrolysis method, and filtration steps all contribute to batch-to-batch variation. These variables make it difficult to compare studies that use different preparations.
Collagen peptides are short chains of amino acids produced by hydrolyzing collagen from animal tissues. The raw material commonly comes from bovine hide, porcine skin, fish skin, or poultry cartilage. Hydrolysis breaks native collagen's triple helix into smaller fragments and increases water solubility relative to intact collagen. The resulting mixture contains peptides of varying lengths rather than a single molecular species; commercial samples are often described by average molecular weight or by a size range. This broad composition affects functional properties such as gelation, foaming, and mouthfeel.
| Property | Value | Notes |
|---|---|---|
| Protein content | ≥90% (dry basis) | Determined by Kjeldahl or Dumas; varies by grade |
| Moisture | ≤10% | Higher moisture reduces shelf life and promotes clumping |
| Heavy metals | Lead ≤2 mg/kg; arsenic ≤1 mg/kg | Limits vary by jurisdiction; tested by ICP-MS |
| Microbial limits | Total aerobic count ≤10^4 CFU/g | Typical specification for food-grade powders |
| Labeling | Hydrolyzed collagen or collagen peptides | Source animal must be declared in many markets |
Quality control for collagen peptides includes measurements of moisture content, ash, protein content, and heavy metals. Microbial limits are set to ensure food or cosmetic grade safety, and the degree of hydrolysis serves as a key process indicator. That indicator correlates with molecular weight distribution and solubility characteristics. Regulatory requirements vary by country, and some jurisdictions restrict label claims about health effects. Documentation such as certificates of analysis and safety data sheets typically accompanies commercial shipments of the material.
Analytical testing of collagen peptides focuses on identity, purity, and molecular weight profile. Size-exclusion chromatography separates peptides by hydrodynamic volume and is often calibrated with known protein standards. Amino acid analysis after acid hydrolysis provides the compositional profile, which can confirm the collagen origin. Mass spectrometry offers detailed sequence information for individual peptides. These methods together help ensure that a product matches its specification and that batch-to-batch variability is controlled.
Dry collagen peptide powder is generally stable when kept in a sealed container away from moisture, heat, and direct sunlight. The powder is hygroscopic and can clump if exposed to humid air, so desiccant packets are sometimes included. In solution, collagen peptides are susceptible to microbial growth unless preserved or refrigerated. Prolonged exposure to high temperatures may cause aggregation or color changes. Typical storage recommendations are cool and dry conditions at ambient temperature.
Several terms describe related products, and their distinctions matter. Gelatin is partially hydrolyzed collagen that still forms a gel when dissolved in hot water and cooled. Collagen peptides, also called collagen hydrolysate, are further broken down and remain soluble without gelling. The term 'collagen' alone usually refers to the intact, insoluble protein. Commercial collagen peptides are often standardized by molecular weight range rather than by a single molecular species, so batch-to-batch variation occurs.
Collagen peptides are short chains of amino acids produced by breaking down native collagen, a structural protein found in skin, bone, and connective tissue. The hydrolysis process cleaves the long triple-helical collagen molecule into smaller fragments. These fragments typically range from about 2 to 20 kilodaltons in molecular weight. Unlike intact collagen, collagen peptides dissolve in water and do not form gels. Commercial preparations appear as powders, granules, or liquids.
The amino acid profile of collagen peptides is distinctive. Glycine is the most abundant residue, followed by proline and hydroxyproline. Hydroxyproline is uncommon in other proteins and serves as a useful marker for collagen content. Cysteine and tryptophan are present only in trace amounts. The exact composition depends on the animal source, such as bovine hide, porcine skin, or fish scales, and on the hydrolysis conditions used. Marine sources often contain lower proline and hydroxyproline levels than mammalian sources.
In August 2022, Lee and Lifeson returned to the stage at the South Park 25th anniversary concert at Red Rocks Amphitheatre, with South Park's co-creator Matt Stone on drums to perform "Closer to the Heart" alongside the members of Primus; this was their first performance since the death of Peart. In September 2022, Lee and Lifeson performed at the London Taylor Hawkins tribute concert with Dave Grohl and Omar Hakim on drums. They performed "2112: Overture", "Working Man", and "YYZ", the latter of which was Hawkins' favourite Rush song. Later in September 2022, Lee and Lifeson played the same set at the second Taylor Hawkins Tribute show in Los Angeles. Grohl was the drummer again on "2112", Chad Smith of the Red Hot Chili Peppers joined them for "Working Man", and Danny Carey from Tool played drums for "YYZ". Those appearances fuelled speculation over a possible Rush reunion, with Paul McCartney (who attended the Hawkins tribute shows) urging Lee and Lifeson to tour again, and Smith commenting, "Those guys are so happy to be playing again... They were part of the show. They loved it and enjoyed the hell out of it. Those guys miss playing.
Watts did not favor the transorbital method, and this difference of opinion contributed to the end of their partnership. Watts resisted the technique itself, Freeman's lack of sterile technique when performing it, and the idea of performing the procedure in an outpatient setting. Watts recalled that the hospital reprimanded Freeman, stating that he was "not a surgeon and if he wants to operate he'll have to apply for surgical privileges." Freeman performed the first transorbital lobotomy on a live patient in 1946. Its simplicity suggested the possibility of carrying it out in mental hospitals lacking the surgical facilities required for the earlier, more complex procedure. (Freeman suggested that, where conventional anesthesia was unavailable, electroconvulsive therapy be used to render the patient unconscious.) In 1947, the Freeman and Watts partnership ended, as the latter was disgusted by Freeman's barbarism and neglectful modifications of the lobotomy from a surgical operation into a simple "office" procedure. Between 1940 and 1944, 684 lobotomies were performed in the United States. However, because of the fervent promotion of the technique by Freeman and Watts, those numbers increased sharply toward the end of the decade. In 1949, the peak year for lobotomies in the US, 5,074 procedures were undertaken, and by 1951 over 18,608 individuals had been lobotomized in the US.
=== Gait === The plantar fascia also has an important role in dynamic function during gait. It was found the plantar fascia continuously elongated during the contact phase of gait. It went through rapid elongation before and immediately after mid-stance, reaching a maximum of 9% to 12% elongation between mid-stance and toe-off. During this phase the plantar fascia behaves like a spring, which may assist in conserving energy. In addition, the plantar fascia has a critical role in normal mechanical function of the foot, contributing to the "windlass mechanism". When the toes are dorsiflexed in the propulsive phase of gait, the plantar fascia becomes tense, resulting in elevation of the longitudinal arch and shortening of the foot (see 3A). One can liken this mechanism to a cable being wound around the drum of a windlass (see 3B); the plantar fascia being the cable, the metatarsal head the drum, and the handle, the proximal phalanx.
== Major products == The company's major products are: Humira (adalimumab) ($9 billion in 2024 revenues, 16% of total revenues), approved to treat autoimmune diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, crohn's disease and ulcerative colitis and administered via injection; Skyrizi (Risankizumab) ($11.7 billion in 2024 revenues, 21% of total revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases; Rinvoq (Upadacitinib) ($6.0 billion in 2023 revenues, 11% of total revenues), used to treat arthritis; and Botox ($6.0 billion in 2024 revenues, 11% of total revenues). Its other major products include Imbruvica (Ibrutinib) to treat cancer ($3.3 billion in 2024 revenues), Vraylar (Cariprazine) to treat schizophrenia and bipolar disorder ($3.3 billion in 2024 revenues), Venclexta (Venetoclax) to treat leukemia and lymphoma ($2.6 billion in 2024 revenues), Mavyret (Glecaprevir/pibrentasvir) to treat Hepatitis C ($1.3 billion in 2024 revenues), and Epkinly (epcoritamab), a blood-cancer therapy developed in partnership with Genmab ($0.1 billion in 2024 revenues). The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev (Foscarbidopa/foslevodopa) and tavapadon.
The Inner London Education Authority (ILEA) was the local education authority for the City of London and the 12 Inner London boroughs from 1965 until its abolition in 1990. From 1965 to 1986 it was an ad hoc committee of the Greater London Council; on 1 April 1986 it was reconstituted as a directly elected body corporate.
Sources: en.wikipedia.org
Reestablishment of slavery by Napoleon Bonaparte. May 1: Law on public education organizes schooling primarily for boys, with male-only teachers; women are barred from entering lycée premises. May 3: Decree specifying domestic servant taxation based on sex and number employed. 1803
== Skin contracture == Wound contraction, where the edges of the skin are pulled together to close the wound, is a normal part of wound healing. However, large wounds and abnormal wound healing cause skin contractures by excessively tightening the skin and limiting movement. A skin contracture due to a burn is known as a burn scar contracture. Large areas of missing skin (such as large burns, grazes, and gouges) drastically reduce the area of skin causing it to become tight when pulled together during wound healing. Scars initially lack elasticity with synthesis of elastic tissue fibres (elastogenesis) being a function of duration and site of the scar. Deep wounds and abnormal wound healing causes abnormal scarring such as hypertrophic scars. Studies on hypertrophic scars have shown a lack of improvement to both elasticity and stiffness suggesting a prolonged healing phase without amelioration seen in a normal wound-healing curve. Surgery can help alleviate skin contractures in the form of skin grafts and removal of hypertrophic scars. For hypertrophic scars, timing is important when considering surgery, as over time scars will mature and may show decreased contractures along with flattening, softening, and repigmentation without surgical intervention.
Dopamine receptor blockade Genetically reduced function of dopamine receptor D2 Sympathoadrenal hyperactivity and autonomic dysfunction It has been proposed that blockade of D2-like (D2, D3 and D4) receptors induce massive glutamate release, generating catatonia, neurotoxicity and myotoxicity. Additionally, the blockade of diverse serotonin receptors by atypical antipsychotics and activation of 5-HT1 receptors by some may reduce GABA release and indirectly induce glutamate release, worsening this proposed glutamatergic neurotoxicity. The muscular symptoms are most likely caused by blockade of the dopamine receptor D2, leading to abnormal function of the basal ganglia similar to that seen in Parkinson's disease. In the past, research and clinical studies seemed to corroborate the D2 receptor blockade theory in which antipsychotic drugs were thought to significantly reduce dopamine activity by blocking the D2 receptors associated with this neurotransmitter. The introduction of atypical antipsychotic drugs, with lower affinity to the D2 dopamine receptors, was thought to have reduced the incidence of NMS. However, recent studies suggest that the decrease in mortality may be the result of increased physician awareness and earlier initiation of treatment rather than the action of the drugs themselves. NMS induced by atypical drugs also resembles "classical" NMS (induced by "typical" antipsychotic drugs), further casting doubt on the overall superiority of these drugs.
The concept of emission and transmission tomography was introduced by David E. Kuhl, Luke Chapman and Roy Edwards in the late 1950s. Their work would lead to the design and construction of several tomographic instruments at Washington University School of Medicine and later at the University of Pennsylvania. In the 1960s and 70s tomographic imaging instruments and techniques were further developed by Michel Ter-Pogossian, Michael E. Phelps, Edward J. Hoffman and others at Washington University School of Medicine. Work by Gordon Brownell, Charles Burnham and their associates at the Massachusetts General Hospital beginning in the 1950s contributed significantly to the development of PET technology and included the first demonstration of annihilation radiation for medical imaging. Their innovations, including the use of light pipes and volumetric analysis, have been important in the deployment of PET imaging. In 1961, James Robertson and his associates at Brookhaven National Laboratory built the first single-plane PET scan, nicknamed the "head-shrinker". One of the factors most responsible for the acceptance of positron imaging was the development of radiopharmaceuticals. In particular, the development of labeled 2-fluorodeoxy-D-glucose (FDG—firstly synthethized and described by two Czech scientists from Charles University in Prague in 1968) by the Brookhaven group under the direction of Al Wolf and Joanna Fowler was a major factor in expanding the scope of PET imaging.
In 1990, the USDA's Food Safety and Inspection Service (FSIS) approved the use of the technology for manufacturing finely textured meat. At the time of its approval, the FSIS called the remaining product "meat", although one FSIS microbiologist dissented, arguing it contained both muscle and connective tissue. In 1994, in response to public health concerns over pathogenic E. coli in beef, the founder of BPI, Eldon Roth, began work on the "pH Enhancement System", which disinfects meat using injected anhydrous ammonia in gaseous form, rapid freezing to 28 °F (−2 °C), and mechanical stress. In 2001, the FSIS approved the gaseous disinfection system as an intermediate step before the roller press freezer, and approved the disinfected product for human consumption, as an additive. The FSIS agreed with BPI's suggestion that ammonia was a "processing agent" which did not need to be listed on labels as an ingredient. FSIS microbiologists Carl Custer and Gerald Zirnstein stated that they argued against the product's approval for human consumption, saying that it was not "meat" but actually "salvage", and that the USDA should seek independent verification of its safety, but they were overruled. In 2003, BPI commissioned a study of the effectiveness and safety of the disinfection process; the Iowa State University researchers found no safety concern in the product or in ground beef containing it. The term "pink slime", a reference to the product's "distinctive look", was coined in 2002 by Zirnstein in an internal FSIS e-mail.
Sources: en.wikipedia.org
In a clinic, up to 80% of patients are women, but this might not necessarily reflect the gender distribution in the entire population. According to Joel Paris, the primary reason for gender disparities in clinical settings is that women are more likely to develop symptoms that prompt them to seek help. Statistics indicate that twice as many women as men in the community experience depression. Conversely, men more frequently meet criteria for substance use disorder and psychopathy, but tend not to seek treatment as often. Additionally, men and women with similar symptoms may manifest them differently. Men frequently exhibit behaviors such as increased alcohol consumption and criminal activity, while women may internalize anger, leading to conditions like depression and self-harm, such as cutting or overdosing. Hence, the gender gap observed in antisocial personality disorder and borderline personality disorder, which may share similar underlying pathologies but present different symptoms influenced by gender. There are also sex differences in personality traits and Axis I and II comorbidity. Men with BPD are more likely to use substances recreationally, have explosive temper, high levels of novelty seeking and have (especially) antisocial, narcissistic, passive–aggressive or sadistic personality traits (male BPD being characterised by antisocial overtones). Women with BPD are more likely to have eating, mood, anxiety, and post-traumatic stress disorders.
=== Canada === In 2026, cottage cheese consumption increased by 15-20% over market levels in recent years, causing a supply shortage in some regions. In 2025, 35,459 tonnes (78,174,000 lb) of cottage cheese were produced in Canada. The Canadian Dairy Commission maintains consumer guidelines and standards for quality manufacturing of cottage cheese.
With access to crystal structures, some scientists have tried to model the structures of other mutants. For example, in German ancestry, where enzymopathy due to G6PD deficiency is rare, mutation sites on G6PD have been shown to lie near the NADP+ binding site, the G6P binding site, and near the interface between the two monomers. Thus, mutations in these critical areas are possible without completely disrupting the function of G6PD. In fact, it has been shown that most disease causing mutations of G6PD occur near the NADP+ structural site.
=== Clinical trials and early approvals for diabetes === In June 2008, a phase II clinical trial began studying semaglutide, a once-weekly diabetes therapy as a longer-acting alternative to liraglutide. It was given the brand name Ozempic. Clinical trials started in January 2016 and ended in May 2017. The US Food and Drug Administration (FDA) approved semaglutide based on evidence from seven clinical trials of 4087 participants with type 2 diabetes. The trials were conducted at 536 sites in 33 countries, including Canada, Mexico, Russia, Ukraine, Turkey, India, South Africa, Japan, Hong Kong, multiple European countries, Argentina, and the United States. In two of these trials (NCT02054897 and NCT02305381), participants were randomly assigned to receive either semaglutide or placebo injection weekly. Neither the participant nor the health care provider knew which treatment was being given until after the trials were completed. Treatment was given for 30 weeks. In the other five trials (NCT01930188, NCT01885208, NCT02128932, NCT02207374, and NCT02254291), participants were randomly assigned to receive either semaglutide or another anti-diabetic medication, and the participant and provider knew which medication was being given in four trials. Treatment was given for 30 weeks or 56 weeks. In each trial, HbA1c was measured from the start of the trial to the end of the trial and compared between the semaglutide group and the other groups.
Many variations of condensation reactions exist. Common examples include the aldol condensation and the Knoevenagel condensation, which both form water as a by-product, as well as the Claisen condensation and the Dieckman condensation (intramolecular Claisen condensation), which form alcohols as by-products.
Sources: en.wikipedia.org
Size-exclusion chromatography is the standard method, often with refractive index or ultraviolet detection. Calibration uses known protein standards. SDS-PAGE can provide a rough range but is less precise.
No. In most countries they are regulated as food ingredients or dietary supplements. They cannot carry claims to treat or prevent disease.
Dry powder should be kept in sealed containers at ambient temperature, away from moisture and direct sunlight. High humidity can cause clumping and microbial growth. Liquid formulations may require refrigeration.
They are usually made from bovine hide, porcine skin, fish skin, or poultry cartilage. The raw collagen is hydrolyzed into shorter peptide chains. Source labeling varies by region and product.